1-2 of 2
Jae Park
Close
Sort by
Journal Articles

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph + acute lymphoblastic leukemia

Clinical Trials & Observations
Anjali S. Advani, Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Journal: Blood Advances
Blood Adv (2023) 7 (7): 1279–1285.
https://doi.org/10.1182/bloodadvances.2022008216
Published: 2023
Includes: Supplemental data
Journal Articles

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Clinical Trials & Observations
Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Šimkovič, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4553–4557.
https://doi.org/10.1182/bloodadvances.2022007812
Published: 2022